Breaking News, Collaborations & Alliances

AbbVie, Galapagos in Cystic Fibrosis Pact

Will contribute technologies to develop combination therapies

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Galapagos NV and AbbVie have entered into a global alliance to discover, develop and commercialize combination therapies in cystic fibrosis (CF). AbbVie and Galapagos will contribute technologies and resources to identify oral compounds that correct the main mutations in CF patients, including F508del and G551D, and/or increase the activity of the cystic fibrosis transmembrane regulator (CFTR) protein. The companies aim to begin Phase I studies at the end of 2014. Following successful clinical d...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters